However, in the CD34−CD10+CD19+CD179a+ population, the number of subpopulations with a stable or increased percentage in the common ALL BCR/ABL+ patients was 0.7 subpopulations/patient, and the RPS of the subpopulations with a stable or increased percentage in the common ALL BCR/ABL+ patients after chemotherapy exhibited a minimum value of 1.01, a medium value of 1.62, and a maximum value of 2.79. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.